Fig. 2
From: Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy
Blockade of the PD-1/PD-L1 interaction by the anti-PD-L1 peptides and antibody. a Blocking profile of the anti-human PD-L1 antibody (R&D, AF156) against human PD-L1 protein. b Blocking profile of the anti-human PD-L1 antibody (R&D, AF156) against DU-145 cells. c Blocking efficiency of the anti-PD-L1 peptides (10 μM) and the anti-human PD-L1 antibody (1 μM) against human PD-L1 protein. d IC50 and blocking efficiency of the peptides and antibody against human PD-L1 protein and human cancer cell line DU-145. e Blocking profiles of the peptides against human PD-L1 protein. f Blocking profiles of the peptides against DU-145 cells. g Blocking efficiency of the peptides and an anti-mouse PD-L1 antibody (BioXcell, 10F.9G2) at 10 μM against a mouse PD-L1 protein. h IC50 and blocking efficiency of the peptides against mouse PD-L1 protein and mouse cancer cell line 4 T1. i Blocking profiles of the peptides against mouse PD-L1 protein. j Blocking profiles of the peptides against mouse cancer cell line 4 T1. Results are represented as the mean ± SD (n = 3)